TG Therapeutics to Participate in the Jefferies Global Healthcare Conference
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference
Fireside chat scheduled for Wednesday, June 5, 2024, at 1:30 PM ET
2024年6月5日星期三東部時間下午1:30舉行交流會
NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the Jefferies Global Healthcare Conference, being held at the Marriott Marquis, in New York City on June 5-6, 2024. The fireside chat is scheduled to take place on Wednesday, June 5, 2024, at 1:30 PM ET.
紐約，2024年6月3日，全球新聞發稿——TG Therapeutics，Inc.（納斯達克：TGTX）今天宣佈，該公司的董事長兼首席執行官Michael S. Weiss將參加Jefferies全球醫療保健大會，該大會於2024年6月5-6日在紐約市萬豪酒店舉行，交流會定於2024年6月5日星期三東部時間下午1:30舉行。
A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company's website at http://ir.tgtherapeutics.com/events.
交流會的現場網絡直播將在該公司網站的投資者和媒體部分的活動頁面（http://ir.tgtherapeutics.com/events）提供。關於TG THERAPEUTICS.
ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received U.S. Food and Drug Administration (FDA) approval for BRIUMVI (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features in Europe and the United Kingdom, respectively. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.
TG Therapeutics是一家完全集成、商業化階段的生物製藥公司，專注於收購、開發和商業化B細胞疾病的新型治療方法。除了研究管線中包含幾種調查藥物外，TG還獲得了美國食品和藥品管理局的批准，使用BRIUMVI（ublituximab-xiiy）治療複發性多發性硬化症的成人患者（RMS），包括臨床分離綜合徵、復發緩解性疾病和活動性繼發性疾病，以及歐洲委員會（EC）和藥品和醫療保健產品監管局（MHRA）批准BRIUMVI用於治療歐洲和英國分別具有臨床或成像特徵的RMS成人患者的活動性疾病。有關詳細信息，請訪問www.tgtherapeutics.com，並在X（前稱Twitter）@TGTherapeutics上關注我們，並在
BRIUMVI是TG Therapeutics，Inc.的註冊商標。LinkedIn.
BRIUMVI is a registered trademark of TG Therapeutics, Inc.
BRIUMVI是tg therapeutics註冊商標。
CONTACT:
聯繫人：
Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4
投資者關係
電子郵件: ir@tgtxinc.com
電話：1.877.575.TGTX（8489），選項4
Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6
媒體關係：
電子郵件: media@tgtxinc.com
電話：1.877.575.TGTX（8489），選項6
譯文內容由第三人軟體翻譯。